Outcomes | Study | P value | Findings | Follow-up time | ||
---|---|---|---|---|---|---|
Non-ERAS vs ERAS | OS | Pang et al. [11] | P = 0.9 | NS | 10 years | |
Ziegelmueller et al. [12] | P = 0.550 | NS | 7 years | |||
Oakley et al. [10] | P = 0.57 | NS | 5 years | |||
Yang et al. [14] | P = 0.007 | ERAS improved OS | 5 years | |||
Ye et al. [13] | P = 0.066 | NS | 3 years | |||
Passeri et al. [16] | P = 0.72 | NS | 2 years | |||
Wang et al. [29] | / | NS | 10–20 months | |||
Zhang et al. [30] | P = 0.035 | ERAS improved OS | 3 years | |||
Quiram et al. [31] | P = 0.464 | NS | 5 years | |||
Zhu et al. [32] | P = 0.810 | NS | 1 year | |||
Tian et al. [33] | P = 0.013 | ERAS improved OS | 5 years | |||
Lohsiriwat et al. [34] | P = 0.014 | ERAS improved OS | 5 years | |||
CSS | Pang et al. [11] | P = 0.9 | NS | 10 years | ||
Ziegelmueller et al. [12] | P = 0.725 | NS | 7 years | |||
Tian et al. [33] | P = 0.033 | ERAS improved CSS | 5 years | |||
DFS | Passeri et al. [16] | P = 0.38 | NS | 2 years | ||
Wang et al. [29] | / | NS | 10–20 months | |||
Zhang et al. [30] | P = 0.007 | ERAS improved DFS | 3 years | |||
Quiram et al. [31] | P = 0.272 | NS | 5 years | |||
Recurrence | Quiram et al. [31] | P = 0.157 | NS | 3 years | ||
Metastasis | Quiram et al. [31] | P = 0.129 | NS | 5 years | ||
Life quality | Physical functioning | Liu et al. [15] | P = 0.038 | ERAS improved life quality | 6 months | |
Nausea/vomiting | P = 0.048 | |||||
Motor dysfunction | P = 0.019 | |||||
RIOT | Failure to RIOT | Day et al. [17] | P = 0.373 | NS | / | |
Days to RIOT | Day et al. [17] | P = 0.134 | NS | |||
Lohsiriwat [18] | P = 0.009 | ERAS reduced interval to RIOT | ||||
Nelson et al. [20] | P = 0.364 | NS | ||||
Li et al. [21] | P = 0.000 | ERAS reduced interval to RIOT | ||||
Rate of on time to RIOT | Hassinger et al. [19] | P = 0.022 | ERAS improved the on-time initiation of RIOT | |||
Rate of completing RIOT | Nelson et al. [20] | P < 0.001 | ERAS improved RIOT completion | |||
High adherence vs low adherence | OS | Gustafsson et al. [23] | P < 0.001 | High adherence improved OS | 5 years | |
Lohsiriwat et al. [34] | P = 0.007 | High adherence improved OS | 5 years | |||
Viannay et al. [22] | P = 0.632 | NS | 3 years | |||
Pisarska et al. [24] | P = 0.0007 | High adherence improved OS | ||||
Rubinkiewicz et al. [26] | P = 0.75 | NS | ||||
Passeri et al. [16] | P = 0.14 | NS | 2 years | |||
CSS | Gustafsson et al. [23] | P = 0.020 | High adherence improved CSS | 5 years | ||
DFS | St-Amour et al. [25] | P = 0.000 | High adherence improved DFS | 3 years | ||
Passeri et al. [16] | P = 0.81 | NS | 2 years | |||
Survival of metastasis | Viannay et al. [22] | P = 0.668 | NS | 3 years | ||
Local recurrence | Gustafsson et al. [23] | P = 0.211 | NS | 5 years | ||
Days to RIOT in young patients | St-Amour et al. [25] | P = 0.001 | High adherence reduced interval to RIOT | 3 years | ||
Alteration of single item within ERAS protocol | OS | Curtis et al. [27] | P = 0.009 | Laparoscopy surgery improved OS | 5 years | |
Wang et al. [29] | / | NS | 10–20 months | |||
DFS | Wang et al. [29] | / | NS | 10–20 months | ||
Local recurrence | Asklid et al. [28] | P = 0.981 | NS | 5 years | ||
OD | P = 0.006 | Restrictive fluid therapy improved survival | ||||
CSD | P = 0.008 | |||||
Days to RIOT | Kato et al. [35] | P = 0.08 | NS | / |